References
- Loupakis F, Cremolini C, Masi G,
et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic
colorectal cancer. N Engl J Med. Oct 23 2014;371(17):1609-18.
doi:10.1056/NEJMoa1403108
- Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with
fluorouracil compared with fluorouracil alone as first-line treatment
for metastatic colorectal cancer: a multicentre randomised trial.
Lancet. Mar 25 2000;355(9209):1041-7.
doi:10.1016/s0140-6736(00)02034-1
- Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of
the anticancer agent CPT-11 to SN-38 by human hepatic microsomal
carboxylesterases and the in vitro assessment of potential drug
interactions. Drug Metab Dispos. Oct 1997;25(10):1157-64.
- Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with
UGT1A1 polymorphisms. Oncology (Williston Park). May 2003;17(5 Suppl
5):52-5.
- Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical
pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer
Res. Aug 2001;7(8):2182-94.
- Guillemette C, Lévesque É, Rouleau M. Pharmacogenomics of human
uridine diphospho-glucuronosyltransferases and clinical implications.
Clin Pharmacol Ther. Sep 2014;96(3):324-39. doi:10.1038/clpt.2014.126
- de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced
diarrhea: functional significance of the polymorphic ABCC2 transporter
protein. Clin Pharmacol Ther. Jan 2007;81(1):42-9.
doi:10.1038/sj.clpt.6100019
- Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the
reduced expression of bilirubin UDP-glucuronosyltransferase 1 in
Gilbert’s syndrome. N Engl J Med. Nov 2 1995;333(18):1171-5.
doi:10.1056/nejm199511023331802
- Jo JC, Lee JL, Ryu MH, et al. Phase II and UGT1A1 genotype study of
irinotecan dose escalation as salvage therapy for advanced gastric
cancer. Br J Cancer. May 8 2012;106(10):1591-7.
doi:10.1038/bjc.2012.143
- Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between
UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also
increase risk. Clin Cancer Res. Aug 1 2010;16(15):3832-42.
doi:10.1158/1078-0432.Ccr-10-1122.
- Zhou CF, Ma T, Su Y, et al. UGT1A1 gene polymorphisms and the
toxicities of FOLFIRI in Chinese Han patients with gastrointestinal
cancer. Anticancer Agents Med Chem. Feb 2013;13(2):235-41.
doi:10.2174/1871520611313020008
- Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts
irinotecan-induced severe toxicities without affecting treatment
outcome and survival in patients with metastatic colorectal carcinoma.
Cancer. May 1 2008;112(9):1932-40. doi:10.1002/cncr.23370
- Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a
determinant of irinotecan disposition and toxicity. Pharmacogenomics
J. 2002;2(1):43-7. doi:10.1038/sj.tpj.6500072
- Atasilp C, Chansriwong P, Sirachainan E, et al. Correlation of
UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia
in Thai colorectal cancer patients. Drug Metab Pharmacokinet. Feb
2016;31(1):90-94. doi:10.1016/j.dmpk.2015.12.004
- Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28
polymorphism in the pharmacodynamics and pharmacokinetics of
irinotecan in patients with metastatic colorectal cancer. J Clin
Oncol. Jul 1 2006;24(19):3061-8. doi:10.1200/jco.2005.05.5400
- Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28
polymorphisms with irinotecan-induced toxicities in colorectal cancer:
a meta-analysis in Caucasians. Pharmacogenomics J. Apr
2014;14(2):120-9. doi:10.1038/tpj.2013.10
- Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28
genotype and irinotecan-induced neutropenia: dose matters. J Natl
Cancer Inst. Sep 5 2007;99(17):1290-5. doi:10.1093/jnci/djm115
- Chen X, Liu L, Guo Z, et al. UGT1A1 polymorphisms with
irinotecan-induced toxicities and treatment outcome in Asians with
Lung Cancer: a meta-analysis. Cancer Chemother Pharmacol. Jun
2017;79(6):1109-1117. doi:10.1007/s00280-017-3306-9
- Mackenzie PI, Bock KW, Burchell B, et al. Nomenclature update for the
mammalian UDP glycosyltransferase (UGT) gene superfamily.
Pharmacogenet Genomics. Oct 2005;15(10):677-85.
doi:10.1097/01.fpc.0000173483.13689.56
- Cheng L, Li M, Hu J, et al. UGT1A1*6 polymorphisms are correlated with
irinotecan-induced toxicity: a system review and meta-analysis in
Asians. Cancer Chemother Pharmacol. Mar 2014;73(3):551-60.
doi:10.1007/s00280-014-2382-3
- Gao J, Zhou J, Li Y, Lu M, Jia R, Shen L. UGT1A1 6/28 polymorphisms
could predict irinotecan-induced severe neutropenia not diarrhea in
Chinese colorectal cancer patients. Med Oncol. 2013;30(3):604.
doi:10.1007/s12032-013-0604-x
- Onoue M, Terada T, Kobayashi M, et al. UGT1A1*6 polymorphism is most
predictive of severe neutropenia induced by irinotecan in Japanese
cancer patients. Int J Clin Oncol. Apr 2009;14(2):136-42.
doi:10.1007/s10147-008-0821-z
- Moriya H, Saito K, Helsby N, et al. Association between the low-dose
irinotecan regimen-induced occurrence of grade 4 neutropenia and
genetic variants of UGT1A1 in patients with gynecological cancers.
Oncol Lett. Jun 2014;7(6):2035-2040. doi:10.3892/ol.2014.2046
- Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic
prediction of irinotecan pharmacokinetics and toxicity in patients
with advanced non-small cell lung cancer. Lung Cancer. Jan
2009;63(1):115-20. doi:10.1016/j.lungcan.2007.12.003
- Jada SR, Lim R, Wong CI, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2
c.421C>A polymorphisms in irinotecan-induced neutropenia
in Asian cancer patients. Cancer Sci. Sep 2007;98(9):1461-7.
doi:10.1111/j.1349-7006.2007.00541.x
- Okuyama Y, Hazama S, Nozawa H, et al. Prospective phase II study of
FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6
polymorphisms. Jpn J Clin Oncol. Apr 2011;41(4):477-82.
doi:10.1093/jjco/hyr001
- Yang C, Liu Y, Xi WQ, et al. Relationship between UGT1A1*6/*28
polymorphisms and severe toxicities in Chinese patients with
pancreatic or biliary tract cancer treated with irinotecan-containing
regimens. Drug Des Devel Ther. 2015;9:3677-83. doi:10.2147/dddt.S86750
- Hirasawa A, Zama T, Akahane T, et al. Polymorphisms in the UGT1A1 gene
predict adverse effects of irinotecan in the treatment of gynecologic
cancer in Japanese patients. J Hum Genet. Dec 2013;58(12):794-8.
doi:10.1038/jhg.2013.105
- Kimura K, Yamano T, Igeta M, et al. UGT1A1 polymorphisms in rectal
cancer associated with the efficacy and toxicity of preoperative
chemoradiotherapy using irinotecan. Cancer Sci. Dec
2018;109(12):3934-3942. doi:10.1111/cas.13807
- Horikawa N, Baba T, Matsumura N, et al. Genomic profile predicts the
efficacy of neoadjuvant chemotherapy for cervical cancer patients. BMC
Cancer. Oct 19 2015;15:739. doi:10.1186/s12885-015-1703-1
- Bai Y, Wu HW, Ma X, Liu Y, Zhang YH. Relationship between UGT1A1*6/*28
gene polymorphisms and the efficacy and toxicity of irinotecan-based
chemotherapy. Onco Targets Ther. 2017;10:3071-3081.
doi:10.2147/ott.S137644
- Treenert A, Areepium N, Tanasanvimon S. Effects of ABCC2 and SLCO1B1
Polymorphisms on Treatment Responses in Thai Metastatic Colorectal
Cancer Patients Treated with Irinotecan-Based Chemotherapy. Asian Pac
J Cancer Prev. Oct 26 2018;19(10):2757-2764.
doi:10.22034/apjcp.2018.19.10.2757
- Haenisch S, Zimmermann U, Dazert E, et al. Influence of polymorphisms
of ABCB1 and ABCC2 on mRNA and protein expression in normal and
cancerous kidney cortex. Pharmacogenomics J. Feb 2007;7(1):56-65.
doi:10.1038/sj.tpj.6500403
- Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2
polymorphisms with irinotecan-pharmacokinetics and clinical outcome in
patients with advanced non-small cell lung cancer. Cancer. Jul 1
2007;110(1):138-47. doi:10.1002/cncr.22760
- Atasilp C, Chansriwong P, Sirachainan E, et al. Effect of drug
metabolizing enzymes and transporters in Thai colorectal cancer
patients treated with irinotecan-based chemotherapy. Sci Rep. Aug 10
2020;10(1):13486. doi:10.1038/s41598-020-70351-0
- Han FF, Guo CL, Yu D, et al. Associations between UGT1A1*6 or
UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian
cancer patients. Cancer Chemother Pharmacol. Apr 2014;73(4):779-88.
doi:10.1007/s00280-014-2405-0
- Yang Y, Zhou M, Hu M, et al. UGT1A1*6 and UGT1A1*28 polymorphisms are
correlated with irinotecan-induced toxicity: A meta-analysis. Asia Pac
J Clin Oncol. Oct 2018;14(5):e479-e489. doi:10.1111/ajco.13028
- Zhang X, Yin JF, Zhang J, Kong SJ, Zhang HY, Chen XM. UGT1A1*6
polymorphisms are correlated with irinotecan-induced neutropenia: a
systematic review and meta-analysis. Cancer Chemother Pharmacol. Jul
2017;80(1):135-149. doi:10.1007/s00280-017-3344-3
- Chen YJ, Hu F, Li CY, et al. The association of UGT1A1*6 and UGT1A1*28
with irinotecan-induced neutropenia in Asians: a meta-analysis.
Biomarkers. Feb 2014;19(1):56-62. doi:10.3109/1354750x.2013.867534
- Zhu X, Ma R, Ma X, Yang G. Association of UGT1A1*6 polymorphism with
irinotecan-based chemotherapy reaction in colorectal cancer patients:
a systematic review and a meta-analysis. Biosci Rep. Oct 30
2020;40(10)doi:10.1042/bsr20200576
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Cochrane Handbook
for Systematic Reviews of Interventions version 6.0. Available online:
www.training.cochrane.org/handbook (assessed on 15 July 2021)
- Wells, G., Shea, B., O’Connell, D., & Peterson, J. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa Hospital
Research Institute. Available online:
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
(accessed on 15 July 2021).
- Biswas M, Kali MSK, Biswas TK,
Ibrahim B. Risk of major adverse cardiovascular events of CYP2C19
loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel
therapy for acute coronary syndrome patients undergoing percutaneous
coronary intervention: a meta-analysis. Platelets. Jul 4
2021;32(5):591-600. doi:10.1080/09537104.2020.1792871
- Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic
reviews. Ann Intern Med. Nov 1 1997;127(9):820-6.
doi:10.7326/0003-4819-127-9-199711010-00008
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency
in meta-analyses. Bmj. Sep 6 2003;327(7414):557-60.
doi:10.1136/bmj.327.7414.557
- Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical
assessment of effect of publication bias on meta-analyses. Bmj. Jun 10
2000;320(7249):1574-7. doi:10.1136/bmj.320.7249.1574
- Ando K, Emi Y, Suenaga T, et al. A prospective study of XELIRI plus
bevacizumab as a first-line therapy in Japanese patients with
unresectable or recurrent colorectal cancer (KSCC1101). Int J Clin
Oncol. Oct 2017;22(5):913-920. doi:10.1007/s10147-017-1140-z
- Bandyopadhyay A, Sharma S, Behera D, Singh N. UGT1A1 Gene
Polymorphisms in Patients with Small Cell Lung Cancer Treated with
Irinotecan-Platinum Doublet Chemotherapy and Their Association with
Gastrointestinal Toxicity and Overall Survival. Oncologist. Mar 16
2021;doi:10.1002/onco.13757
- Choi YH, Kim TW, Kim KP, et al. A Phase II study of clinical outcomes
of 3-week cycles of irinotecan and S-1 in patients with previously
untreated metastatic colorectal cancer: influence of the UGT1A1 and
CYP2A6 polymorphisms on clinical activity. Oncology. 2012;82(5):290-7.
doi:10.1159/000337989
- Deng B, Jia L, Tan H, et al. Effects of Shengjiangxiexin decoction on
irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6
polymorphisms. J Tradit Chin Med. Feb 2017;37(1):35-42.
doi:10.1016/s0254-6272(17)30024-9
- Gao J, Zhou J, Li Y, et al. Associations between UGT1A1*6/*28
polymorphisms and irinotecan-induced severe toxicity in Chinese
gastric or esophageal cancer patients. Med Oncol. 2013;30(3):630.
doi:10.1007/s12032-013-0630-8
- Minami H, Sai K, Saeki M, et al. Irinotecan
pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in
Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. Jul
2007;17(7):497-504. doi:10.1097/FPC.0b013e328014341f
- Liu D, Li J, Gao J, Li Y, Yang R, Shen L. Examination of multiple
UGT1A and DPYD polymorphisms has limited ability to predict the
toxicity and efficacy of metastatic colorectal cancer treated with
irinotecan-based chemotherapy: a retrospective analysis. BMC Cancer.
Jun 20 2017;17(1):437. doi:10.1186/s12885-017-3406-2
- Matsuoka H, Murakami R, Abiko K, et al. UGT1A1 polymorphism has a
prognostic effect in patients with stage IB or II uterine cervical
cancer and one or no metastatic pelvic nodes receiving irinotecan
chemotherapy: a retrospective study. BMC Cancer. Aug 5 2020;20(1):729.
doi:10.1186/s12885-020-07225-1
- Li M, Wang Z, Guo J, et al. Clinical significance of UGT1A1 gene
polymorphisms on irinotecan-based regimens as the treatment in
metastatic colorectal cancer. Onco Targets Ther. 2014;7:1653-61.
doi:10.2147/ott.S67867
- Nakamura Y, Soda H, Oka M, et al. Randomized phase II trial of
irinotecan with paclitaxel or gemcitabine for non-small cell lung
cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
J Thorac Oncol. Jan 2011;6(1):121-7. doi:10.1097/JTO.0b013e318200e4e8
- Park SR, Kong SY, Rhee J, et al. Phase II study of a triplet regimen
of S-1 combined with irinotecan and oxaliplatin in patients with
metastatic gastric cancer: clinical and pharmacogenetic results. Ann
Oncol. Apr 2011;22(4):890-896. doi:10.1093/annonc/mdq435
- Peng H, Duan Z, Pan D, Wen J, Wei X. UGT1A1 Gene Polymorphism Predicts
Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer
Patients. Clin Lab. Sep 1 2017;63(9):1339-1346.
doi:10.7754/Clin.Lab.2017.170105
- Satoh T, Ura T, Yamada Y, et al. Genotype-directed, dose-finding study
of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6
polymorphisms. Cancer Sci. Oct 2011;102(10):1868-73.
doi:10.1111/j.1349-7006.2011.02030.x
- Shi Y, Hu Y, Hu X, Li X, Lin L, Han X. Cisplatin combined with
irinotecan or etoposide for untreated extensive-stage small cell lung
cancer: A multicenter randomized controlled clinical trial. Thorac
Cancer. Nov 2015;6(6):785-91. doi:10.1111/1759-7714.12303
- Chen S, Hua L, Feng C, et al. Correlation between UGT1A1 gene
polymorphism and irinotecan chemotherapy in metastatic colorectal
cancer: a study from Guangxi Zhuang. BMC Gastroenterol. Apr 7
2020;20(1):96. doi:10.1186/s12876-020-01227-w
- Sunakawa Y, Ichikawa W, Fujita K, et al. UGT1A1*1/*28 and *1/*6
genotypes have no effects on the efficacy and toxicity of FOLFIRI in
Japanese patients with advanced colorectal cancer. Cancer Chemother
Pharmacol. Aug 2011;68(2):279-84. doi:10.1007/s00280-010-1485-8
- Takahara N, Nakai Y, Isayama H, et al. Uridine diphosphate
glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1)
polymorphisms are associated with toxicity and efficacy in irinotecan
monotherapy for refractory pancreatic cancer. Cancer Chemother
Pharmacol. Jan 2013;71(1):85-92. doi:10.1007/s00280-012-1981-0
- Takano M, Kato M, Yoshikawa T, et al. Clinical significance of
UDP-glucuronosyltransferase 1A1*6 for toxicities of combination
chemotherapy with irinotecan and cisplatin in gynecologic cancers: a
prospective multi-institutional study. Oncology. 2009;76(5):315-21.
doi:10.1159/000209335
- Yamaguchi T, Iwasa S, Shoji H, et al. Association between UGT1A1 gene
polymorphism and safety and efficacy of irinotecan monotherapy as the
third-line treatment for advanced gastric cancer. Gastric Cancer. Jul
2019;22(4):778-784. doi:10.1007/s10120-018-00917-5
- Wang Y, Shen L, Xu N, et al. UGT1A1 predicts outcome in colorectal
cancer treated with irinotecan and fluorouracil. World J
Gastroenterol. Dec 7 2012;18(45):6635-44. doi:10.3748/wjg.v18.i45.6635
- Wang Y, Yi C, Wang Y, et al. Distribution of uridine diphosphate
glucuronosyltransferase 1A polymorphisms and their role in
irinotecan-induced toxicity in patients with cancer. Oncol Lett. Nov
2017;14(5):5743-5752. doi:10.3892/ol.2017.6933
- Xiao XG, Xia S, Zou M, et al. The relationship between UGT1A1 gene
polymorphism and irinotecan effect on extensive-stage small-cell lung
cancer. Onco Targets Ther. 2015;8:3575-83. doi:10.2147/ott.S95149
- Xu C, Tang X, Qu Y, Keyoumu S, Zhou N, Tang Y. UGT1A1 gene
polymorphism is associated with toxicity and clinical efficacy of
irinotecan-based chemotherapy in patients with advanced colorectal
cancer. Cancer Chemother Pharmacol. Jul 2016;78(1):119-30.
doi:10.1007/s00280-016-3057-z
- Ma X, Han S, Liu Y, Liu JT, Fang J, Zhang YH. Pharmacogenetic impact
of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated
with metronomic irinotecan-based chemotherapy in Chinese populations.
J Pharm Pharmacol. Nov 2020;72(11):1528-1535. doi:10.1111/jphp.13333
- Xu Q, Ding YY, Song LX, Xu JF. Correlation of UGT1A1 and ERCC1 gene
polymorphisms with the outcome of combined irinotecan plus cisplatin
treatment in recurrent ovarian cancer. Genet Mol Res. Jun 29
2015;14(2):7241-7. doi:10.4238/2015.June.29.17
- Yamamoto N, Takahashi T, Kunikane H, et al. Phase I/II pharmacokinetic
and pharmacogenomic study of UGT1A1 polymorphism in elderly patients
with advanced non-small cell lung cancer treated with irinotecan. Clin
Pharmacol Ther. Feb 2009;85(2):149-54. doi:10.1038/clpt.2008.152
- Lu YY, Huang XE, Wu XY, et al. Clinical observations on associations
between the UGT1A1 genotype and severe toxicity of irinotecan. Asian
Pac J Cancer Prev. 2014;15(7):3335-41.
doi:10.7314/apjcp.2014.15.7.3335
- Yun F, Lulu M, Zhiyu H, et al. Uridine diphosphate glucuronide
transferase 1A1FNx0128 gene polymorphism and the toxicity of
irinotecan in recurrent and refractory small cell lung cancer. J
Cancer Res Ther. Nov 2014;10 Suppl:C195-200.
doi:10.4103/0973-1482.145871.
- Dean L. Irinotecan Therapy and UGT1A1 Genotype. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK294473/ (accessed on 15 July
2021).
- Fukui T, Mitsufuji H, Kubota M, et al. Prevalence of topoisomerase I
genetic mutations and UGT1A1 polymorphisms associated with irinotecan
in individuals of Asian descent. Oncol Lett. Sep 1 2011;2(5):923-928.
doi:10.3892/ol.2011.346
Table 1 . Baseline characteristics of included studies